文献速递甲状腺疾病

放射性碘给药时机不影响分化型甲状腺癌患者的结局

Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
PubMed 文献 · Thyroid · 2016-09-22

本研究纳入545例接受放射性碘治疗的分化型甲状腺癌患者,按全甲状腺切除至放射性碘间隔分为≤6个月组(A组,n=295)和>6个月组(B组,n=250)。初始治疗后1年,A组59.3%与B组65.6%患者无病(p=0.15),中位随访6年结果不变;多因素logistic回归显示放射性碘时机与持续疾病无关(相对危险度0.97,置信区间0.80-1.19)。

要点

  • 全甲状腺切除至放射性碘间隔≤6个月与>6个月两组,1年无病比例无显著差异(59.3% vs 65.6%,p=0.15)。
  • 高危亚组(n=72)无病比例亦相似(9.5% vs 10.0%,p=1.0)。
  • 放射性碘时机与持续疾病无关(相对危险度0.97,置信区间0.80-1.19)。

核心结论

  • 放射性碘给药时机似乎不影响分化型甲状腺癌的疾病结局,可在考虑卫生系统物流的情况下安全安排。

研究设计与样本

  • 本研究评估了一个接受放射性碘治疗且有疾病状态数据的分化型甲状腺癌患者队列,共纳入545例,按全甲状腺切除至放射性碘间隔分为A组≤6个月(中位3个月,n=295)和B组>6个月(中位10.5个月,n=250)。

主要发现

  • 两组性别、组织学类型、肿瘤大小、远处转移或放射性碘剂量无差异(p>0.1)。
  • B组患者年龄更大(47.1 vs 43.1岁,p=0.02),颈部转移更少(73.6% vs 59.3%,p=0.002),更常被归类为低ATA风险(48.0% vs 36.6%,p=0.027)。
  • 初始治疗后1年,A组59.3%与B组65.6%患者被判定为无病(p=0.15)。
  • 高危亚组(n=72)无病比例相似(9.5% vs 10.0%,p=1.0)。
  • 中位随访6年后这些发现未改变;多因素logistic回归显示放射性碘时机与持续疾病无关(相对危险度0.97,置信区间0.80-1.19)。

关键数值与推荐

  • 无病定义为无甲状腺癌的临床、影像学或生化证据。
  • TNM分期:I期322例(59.1%),II期62例(11.4%),III期65例(11.9%),IV期82例(15.0%)。
  • 全甲状腺切除至放射性碘的中位间隔为6个月(P25-75:3-10个月)。

临床怎么用

  • 作者结论认为放射性碘时机似乎不影响分化型甲状腺癌的疾病结局,可在考虑卫生系统物流的情况下安全安排。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioactive iodine (RAI) is widely used in the management of differentiated thyroid cancer (DTC). The impact of the time interval between total thyroidectomy (TT) and RAI administration on disease outcome remains controversial. The objective of the present study was to evaluate the impact of the time interval between TT and RAI. METHODS: This study evaluated a cohort of DTC patients who received RAI therapy for whom data on disease status were available. Patients were allocated to one of two groups, according to the time interval between TT and RAI. "Disease-free" was defined as no clinical, imaging, or biochemical evidence of thyroid cancer. RESULTS: The study included 545 individuals. The TNM stages were: 322 (59.1%) patients in Stage I, 62 (11.4%) in Stage II, 65 (11.9%) in Stage III, and 82 (15.0%) in Stage IV. The median time interval between TT and RAI was six months (P25-75: 3-10 months). Patients were allocated to one of two groups according to RAI timing administration: group A ≤6 months after TT (median 3 months; n = 295), or group B >6 months after TT (median 10.5 months; n = 250). There were no differences for sex, histological type, tumor size, distant metastasis, or RAI dose between the groups (p > 0.1). Patients in group B were older (47.1 vs. 43.1 years; p = 0.02), had less cervical metastasis (73.6% vs. 59.3%; p = 0.002), and were more commonly classified as low ATA risk (48.0% vs. 36.6%; p = 0.027). One year after initial therapy, 59.3% and 65.6% of patients in groups A and B, respectively, were considered disease-free (p = 0.15). Remarkably, the percentage of patients classified as disease-free was similar, even when analyzing a subgroup of high-risk patients (n = 72; 9.5% vs. 10.0%; p = 1.0). These findings did not change after a median of six years of follow-up. Accordingly, further analysis by multiple logistic regression showed that timing of RAI was not associated with persistent disease (relative risk 0.97 [confidence interval 0.80-1.19]). CONCLUSIONS: Timing of RAI does not seem to interfere with the disease outcomes in DTC and can therefore be safely planned while taking into account the health system logistics.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Scheffel RS, Zanella AB, Dora JM, et al. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma. Thyroid. 2016. PMID: 27549175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。